Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1248

1.

Balanced Dysfunction in the Healthcare Ecosystem Harms Patients.

Califf RM.

Circulation. 2019 Dec 3;140(23):1860-1864. doi: 10.1161/CIRCULATIONAHA.119.043935. Epub 2019 Dec 2. No abstract available.

PMID:
31790300
2.

Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.

Brennan JM, Wruck L, Pencina MJ, Clare RM, Lopes RD, Alexander JH, O'Brien S, Krucoff M, Rao SV, Wang TY, Curtis LH, Newby LK, Granger CB, Patel M, Mahaffey K, Ross JS, Normand SL, Eloff BC, Caños DA, Lokhnygina YV, Roe MT, Califf RM, Marinac-Dabic D, Peterson ED.

Am Heart J. 2019 Dec;218:110-122. doi: 10.1016/j.ahj.2019.09.002. Epub 2019 Sep 12.

PMID:
31726314
3.

Facilitating translational team science: The project leader model.

Sutton L, Berdan LG, Bolte J, Califf RM, Ginsburg GS, Li JS, McCall J, Moen R, Myers BS, Rodriquez V, Veldman T, Boulware LE.

J Clin Transl Sci. 2019 Aug 28;3(4):140-146. doi: 10.1017/cts.2019.398. eCollection 2019 Aug.

4.

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.

Marquis-Gravel G, Roe MT, Turakhia MP, Boden W, Temple R, Sharma A, Hirshberg B, Slater P, Craft N, Stockbridge N, McDowell B, Waldstreicher J, Bourla A, Bansilal S, Wong JL, Meunier C, Kassahun H, Coran P, Bataille L, Patrick-Lake B, Hirsch B, Reites J, Mehta R, Muse ED, Chandross KJ, Silverstein JC, Silcox C, Overhage JM, Califf RM, Peterson ED.

Circulation. 2019 Oct 22;140(17):1426-1436. doi: 10.1161/CIRCULATIONAHA.119.040798. Epub 2019 Oct 21.

PMID:
31634011
5.

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, Hernandez AF, Matsouaka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2019 Nov;7(11):980-992. doi: 10.1016/j.jchf.2019.07.011. Epub 2019 Oct 9.

PMID:
31606362
6.

Consent for Research Participation in Practice.

Califf RM.

Am J Bioeth. 2019 Apr;19(4):19-21. doi: 10.1080/15265161.2019.1574492. No abstract available.

PMID:
31544682
7.

Oral Fluoroquinolones.

Califf RM.

J Am Coll Cardiol. 2019 Sep 17;74(11):1451-1453. doi: 10.1016/j.jacc.2019.08.002. No abstract available.

PMID:
31514946
8.

Proposals to Lower Medication Costs-Reply.

Califf RM, Slavitt A.

JAMA. 2019 Sep 10;322(10):982-983. doi: 10.1001/jama.2019.10395. No abstract available.

PMID:
31503306
9.

Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials: It Is Time to Get Practical.

Rodriguez F, Califf RM, Harrington RA.

JAMA Cardiol. 2019 Sep 1. doi: 10.1001/jamacardio.2019.3922. [Epub ahead of print] No abstract available.

PMID:
31473764
10.

High-quality evidence to inform clinical practice.

Fanaroff AC, Califf RM, Lopes RD.

Lancet. 2019 Aug 24;394(10199):633-634. doi: 10.1016/S0140-6736(19)31256-5. No abstract available. Erratum in: Lancet. 2019 Sep 14;394(10202):918.

PMID:
31448730
11.

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.

Qamar A, Giugliano RP, Bohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DA.

J Am Coll Cardiol. 2019 Aug 27;74(8):1057-1068. doi: 10.1016/j.jacc.2019.06.038.

PMID:
31439215
12.

Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review.

Starks MA, Sanders GD, Coeytaux RR, Riley IL, Jackson LR 2nd, Brooks AM, Thomas KL, Choudhury KR, Califf RM, Hernandez AF.

PLoS One. 2019 Aug 12;14(8):e0219894. doi: 10.1371/journal.pone.0219894. eCollection 2019.

13.

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.

Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA.

JAMA Cardiol. 2019 Jul 17. doi: 10.1001/jamacardio.2019.2306. [Epub ahead of print]

PMID:
31314050
14.

The digital transformation of medicine can revitalize the patient-clinician relationship.

Warraich HJ, Califf RM, Krumholz HM.

NPJ Digit Med. 2018 Sep 20;1:49. doi: 10.1038/s41746-018-0060-2. eCollection 2018. Review.

15.

Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example.

Yang S, Starks MA, Hernandez AF, Turner EL, Califf RM, O'Connor CM, Mentz RJ, Roy Choudhury K.

Contemp Clin Trials. 2019 Jun 20;88:105775. doi: 10.1016/j.cct.2019.04.016. [Epub ahead of print]

PMID:
31228563
16.

Employ Cybersecurity Techniques Against the Threat of Medical Misinformation.

Perakslis E, Califf RM.

JAMA. 2019 Jul 16;322(3):207-208. doi: 10.1001/jama.2019.6857. No abstract available.

PMID:
31199429
17.

Filling in the Evidence About Sunscreen.

Califf RM, Shinkai K.

JAMA. 2019 Jun 4;321(21):2077-2079. doi: 10.1001/jama.2019.5528. No abstract available.

PMID:
31058950
18.

Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation.

Califf RM, Slavitt A.

JAMA. 2019 Apr 23;321(16):1571-1573. doi: 10.1001/jama.2019.3846. No abstract available.

PMID:
31012911
19.

Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018.

Fanaroff AC, Califf RM, Windecker S, Smith SC Jr, Lopes RD.

JAMA. 2019 Mar 19;321(11):1069-1080. doi: 10.1001/jama.2019.1122.

20.

Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map.

Greene SJ, Califf RM.

JACC Heart Fail. 2019 Apr;7(4):347-349. doi: 10.1016/j.jchf.2018.12.012. Epub 2019 Feb 6. No abstract available.

PMID:
30738979
21.

Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association.

McClellan M, Brown N, Califf RM, Warner JJ.

Circulation. 2019 Feb 26;139(9):e44-e54. doi: 10.1161/CIR.0000000000000652.

PMID:
30674212
22.

Work and Cardiovascular Disease in China.

Warraich HJ, Wang TY, Califf RM.

JAMA Netw Open. 2018 Nov 2;1(7):e184815. doi: 10.1001/jamanetworkopen.2018.4815. No abstract available.

PMID:
30646373
23.

Medication Discontinuation in the IMPROVE-IT Trial.

Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041.

PMID:
30630361
24.

Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency.

Califf RM, Hamburg M, Henney JE, Kessler DA, McClellan M, von Eschenbach AC, Young F.

Health Aff (Millwood). 2019 Jan;38(1):84-86. doi: 10.1377/hlthaff.2018.05185.

PMID:
30615515
25.

Differences in Health Outcomes between Men and Women: Biological, Behavioral, and Societal Factors.

Warraich HJ, Califf RM.

Clin Chem. 2019 Jan;65(1):19-23. doi: 10.1373/clinchem.2018.287334. No abstract available.

PMID:
30602470
26.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD.

Circulation. 2019 Feb 12;139(7):863-873. doi: 10.1161/CIRCULATIONAHA.118.037202.

PMID:
30586739
27.

Providing Individual Research Results to Participants-Reply.

Wong CA, Hernandez AF, Califf RM.

JAMA. 2018 Dec 25;320(24):2601. doi: 10.1001/jama.2018.18111. No abstract available.

PMID:
30575874
28.

Improving Clinical Outcomes in the Era of Information Ubiquity.

Califf RM.

J Am Soc Nephrol. 2019 Jan;30(1):7-12. doi: 10.1681/ASN.2018111128. No abstract available.

PMID:
30573637
29.

Future of Personalized Cardiovascular Medicine: JACC State-of-the-Art Review.

Califf RM.

J Am Coll Cardiol. 2018 Dec 25;72(25):3301-3309. doi: 10.1016/j.jacc.2018.09.079. Review.

PMID:
30573033
30.

Standardized classification and framework for reporting and interpreting medication non-adherence in clinical trials.

Senatore FF, Califf RM.

Eur Heart J. 2019 Jul 1;40(25):2086-2088. doi: 10.1093/eurheartj/ehy759. No abstract available.

PMID:
30496403
31.

The evolution of PCI registries: implementing a sustainable future for health systems and clinicians.

Rymer JA, Califf RM.

EuroIntervention. 2018 Nov 20;14(10):1076-1079. doi: 10.4244/EIJV14I10A193. No abstract available.

32.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

33.

A Beginning to Principles of Ethical and Regulatory Oversight of Patient-Centered Research.

Califf RM.

Ann Intern Med. 2018 Oct 16;169(8):579-580. doi: 10.7326/M18-2517. Epub 2018 Sep 25. No abstract available.

PMID:
30264090
34.

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.

Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovec AM, Roe MT, Blazing MA.

Am J Cardiol. 2018 Nov 1;122(9):1451-1458. doi: 10.1016/j.amjcard.2018.07.034. Epub 2018 Aug 4.

PMID:
30180960
35.

Individual risk prediction using data beyond the medical clinic.

Califf RM, Harrell FE Jr.

CMAJ. 2018 Aug 13;190(32):E947-E948. doi: 10.1503/cmaj.180967. No abstract available.

36.

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials.

Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM.

JACC Heart Fail. 2018 Aug;6(8):619-632. doi: 10.1016/j.jchf.2018.06.008. Review.

37.

Return of Research Results to Study Participants: Uncharted and Untested.

Wong CA, Hernandez AF, Califf RM.

JAMA. 2018 Aug 7;320(5):435-436. doi: 10.1001/jama.2018.7898. No abstract available.

PMID:
29931289
38.

Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full.

Califf RM.

Clin Trials. 2018 Jun;15(3):235-239. doi: 10.1177/1740774518771347. No abstract available.

PMID:
29871505
39.

Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?

Jones DW, Luft FC, Whelton PK, Alderman MH, Hall JE, Peterson ED, Califf RM, McCarron DA.

Hypertension. 2018 Jul;72(1):10-11. doi: 10.1161/HYPERTENSIONAHA.118.11103. Epub 2018 May 7. Review. No abstract available. Erratum in: Hypertension. 2018 Sep;72(3):e35. Hypertension. 2019 Jan;73(1):e8.

40.

Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe.

Fanaroff AC, Steffel J, Alexander JH, Lip GYH, Califf RM, Lopes RD.

Eur Heart J. 2018 Aug 21;39(32):2932-2941. doi: 10.1093/eurheartj/ehy236. Review.

PMID:
29688403
41.

Remembering Dr Ray Lipicky.

Califf RM, Temple R.

Circulation. 2018 Mar 27;137(13):1309. doi: 10.1161/CIRCULATIONAHA.118.034595. No abstract available.

PMID:
29581359
42.

Mass Customization, Ubiquitous Information, and Improvements to Health Outcomes in the United States.

Califf RM.

JAMA Cardiol. 2018 May 1;3(5):365-366. doi: 10.1001/jamacardio.2017.5354. No abstract available.

PMID:
29516101
43.

Biomarker definitions and their applications.

Califf RM.

Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. doi: 10.1177/1535370217750088. Review.

44.

Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.

O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM.

J Am Coll Cardiol. 2018 Jan 30;71(4):443-453. doi: 10.1016/j.jacc.2017.11.048. Review.

45.

Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension: Bull's-eye or Painting the Target Around the Arrow?

Califf RM.

JAMA Intern Med. 2018 Jan 1;178(1):63-65. doi: 10.1001/jamainternmed.2017.5091. No abstract available.

PMID:
29159401
46.

Finding ideal blood pressure targets in ischaemic stroke: prospective insight or retrospective guesswork?

Califf RM.

Eur Heart J. 2017 Oct 1;38(37):2836-2837. doi: 10.1093/eurheartj/ehx415. No abstract available.

PMID:
28982229
47.

Balancing the Need for Access With the Imperative for Empirical Evidence of Benefit and Risk.

Califf RM.

JAMA. 2017 Aug 15;318(7):614-616. doi: 10.1001/jama.2017.9412. No abstract available.

PMID:
28810004
48.

Cosmetics, Regulations, and the Public Health: Understanding the Safety of Medical and Other Products.

Califf RM, McCall J, Mark DB.

JAMA Intern Med. 2017 Aug 1;177(8):1080-1082. doi: 10.1001/jamainternmed.2017.2773. No abstract available.

PMID:
28655035
49.

Evaluating Evolving Technologies in a Time of Rapid Change: The Case of Transcatheter Aortic Valve Replacement.

Califf RM.

JAMA Cardiol. 2017 Aug 1;2(8):830-831. doi: 10.1001/jamacardio.2017.1733. No abstract available.

PMID:
28636721
50.

Warning About Shortcuts in Drug Development.

Califf RM.

J Am Heart Assoc. 2017 Mar 21;6(3). pii: e005737. doi: 10.1161/JAHA.117.005737. No abstract available.

Supplemental Content

Loading ...
Support Center